We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Luminex Corporation | NASDAQ:LMNX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 36.99 | 36.94 | 36.98 | 0 | 01:00:00 |
From Jul 2019 to Jul 2024
By Donato Paolo Mancini
Germany's Merck KGaA (MRK.XE) has agreed to sell its flow cytometry unit to Luminex Corp. (LMNX) for EUR62.5 million ($72.12 million).
Cytometry is the measurement of the characteristics of cells.
Upon completion, Luminex will own the flow cytometry platforms Amnis and Guava, as well as the associated reagents under those brands. The transaction includes the transfer of 148 employees who are for the most part based in the Seattle area, a spokesman told Dow Jones Newswires.
"This is an exciting opportunity for both of our organizations and I would like to extend my sincerest thanks to our committed colleagues," said Udit Batra, member of the Merck Executive Board and CEO, Life Science.
Closing of the transaction is expected by the end of 2018, subject to customary closing conditions.
Write to Donato Paolo Mancini at donatopaolo.mancini@dowjones.com
(END) Dow Jones Newswires
October 18, 2018 06:48 ET (10:48 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Luminex Chart |
1 Month Luminex Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
